← Torna allo Screener

Innoviva

INVA Small Cap

Healthcare · Biotechnology

Aggiornato: May 2, 2026, 22:05 UTC

19,71 €
+0.52% oggi
52W: 14,09 € – 21,45 €
52W Low: 14,09 € Posizione: 76.4% 52W High: 21,45 €

Metriche Chiave

P/E Ratio
7x
Rapporto P/E
Forward P/E
10.46x
P/E Forward
P/S Ratio
4.16x
Prezzo/Vendite
EV/EBITDA
7.57x
Valore Impresa/EBITDA
Rendimento Dividendi
Rendimento annuale da dividendi
Cap. di Mercato
1,5 Mrd. €
Capitalizzazione di Mercato
Crescita Ricavi
24.8%
Crescita Ricavi Anno su Anno
Margine di Profitto
65.92%
Margine Netto
ROE
29.09%
Return on Equity
Beta
0.4
Sensibilità al mercato
Interesse Corto
12.23%
% del flottante in vendita allo scoperto
Volume Medio
747,600
Volume Medio Giornaliero

Analisi della Valutazione

Segnale
Sottovalutata
vs. P/E medio S&P 500 (24,7x)
Consenso degli Analisti
None
5 analisti
Prezzo Obiettivo Medio
28,32 €
+43.66% potenziale
Range Obiettivo
15,35 € – 39,24 €

Informazioni sull'Azienda

Settore: Healthcare Industria: Biotechnology Paese: United States Dipendenti: 159 Borsa: NMS

Innoviva Stock at a Glance

Innoviva (INVA) is currently trading at 19,71 € with a market capitalization of 1,5 Mrd. €. The trailing P/E ratio stands at 7x, with a forward P/E of 10.46x. The 52-week range spans from 14,09 € to 21,45 €; the current price is 8.1% below the yearly high. Year-over-year revenue growth stands at +24.8%. The net profit margin stands at 65.92%.

💰 Dividendo

Innoviva currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Raccomandazioni degli Analisti

5 analysts rate Innoviva (INVA) on consensus: None. The average price target is 28,32 €, implying +43.66% from the current price. Analyst price targets range from 15,35 € to 39,24 €.

Tesi di Investimento: Punti di Forza e Debolezze

Punti di Forza
  • Strong revenue growth of 24.8% YoY
  • Profitable with 65.92% net margin
  • High return on equity (29.09% ROE)
  • High gross margin of 74.94% — indicates pricing power
  • Currently flagged as undervalued
  • Solid balance sheet with low debt (D/E 28.24)
  • Positive free cash flow
Debolezze
  • High short interest (12.23%)

Panoramica Tecnica

MM 50 Giorni
19,63 €
+0.43% vs. prezzo
MM 200 Giorni
17,56 €
+12.29% vs. prezzo
Sotto Massimo 52S
−8.1%
21,45 €
Sopra Minimo 52S
+39.9%
14,09 €

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profilo di Rischio

Rischio di Mercato (Beta)
0.4 · Defensive
Moves less than the overall market
Short Interest
12.23% · High
% del flottante in vendita allo scoperto
Debt-to-Equity
28.24 · Low
Debito totale / patrimonio

The data points to relatively defensive market behavior, elevated short interest (12.23%).

Dati di Trading

50-Day MA: 19,63 €
200-Day MA: 17,56 €
Volume: 390,759
Volume Medio: 747,600
Ratio Corto: 8.58
Rapporto P/B: 1.47x
Debito/Patrimonio: 28.24x
Flusso di Cassa Libero: 104 M €

Where can I buy Innoviva?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Scroll to Top